<DOC>
	<DOCNO>NCT01398423</DOCNO>
	<brief_summary>A randomized , double-blind , active control trial determine safety , efficacy pharmacokinetics INV-144 versus losartan potassium plus placebo subject hypertension Type 2 diabetes mellitus nephropathy evidence albuminuria .</brief_summary>
	<brief_title>INV-144 Versus Losartan Hypertension Type 2 Diabetes Mellitus Patients With Macroalbuminuria</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , parallel-group , active-control trial design evaluate safety efficacy INV-144 versus losartan plus placebo co-administered daily 12 week subject type 2 diabetes hypertension nephropathy evidence albuminuria . Approximately 92 adult subject enrol randomized 1:1 ratio receive either INV-144 losartan plus placebo daily 12 week . The goal approximately 80 subject complete entire study . The trial consist 4-week open-label losartan run-in period , 12-week double-blind active treatment period , 4-week safety follow-up period . Efficacy evaluate measurement UACR , systolic diastolic blood pressure , HOMA-IR ratio . Safety monitor throughout study evaluation adverse event ( AEs ) , physical examination ( PEs ) , clinical laboratory result , vital sign , electrocardiogram ( ECGs ) . Blood sample PK analysis obtain subset approximately 22 subject , 2 4 site , ensure PK data obtain minimum 9 subject treatment arm .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Men woman , 18 85 year age , inclusive . 2 . Able willing understand provide write informed consent . 3 . Documented hypertension define 1 following : Currently treat antihypertensive medication , Untreated seat systolic blood pressure ( mean 3 reading ) 126 180 millimeter mercury ( mm Hg ) . 4 . Documented type 2 diabetes mellitus define 1 follow : Currently treat antidiabetic medication ( oral and/or insulin ) , Fasting serum glucose level ≥126 mg/dL . 5 . Documented nephropathy evidence UACR 300 3000 mg/g . 6 . Both men woman child bear potential ( i.e. , surgically sterile postmenopausal define age &gt; 40 year without menses ≥2 year ) must agree use 1 follow form reliable contraception : Abstinence , mean total lack sexual activity , Oral contraceptives ( `` pill '' ) hormonal contraceptive method , Intrauterine device , Doublebarrier method ( diaphragm condom plus spermicidal cream ) , If female , male partner sterilization . 1 . Required use ACE inhibitor , ARB , direct renin inhibitor , aldosterone antagonist study drug , study . 2 . Systolic blood pressure &gt; 180 mm Hg ( mean 3 seat reading , 5 minute apart , use subject 's dominant arm ) . 3 . Chronic kidney disease stage 4 high define estimate glomerular filtration rate &lt; 30 mL/min per 1.73 m2 ( abbreviate MDRD equation ) . 4 . Hepatic impairment define serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal . 5 . Diagnosis type 1 diabetes nondiabetic renal disease , include limited renalartery stenosis , primary glomerular disease , autoimmune renal disease , etc . 6 . Severe anemia define hemoglobin &lt; 8 g/dL . 7 . Congestive heart failure New York Heart Association Class II , III , IV symptom . 8 . Thiamine ( Vitamin B1 ) deficiency know alcohol abuse within past year . If alcohol abuse suspect , subject must normal thiamine blood level document prior study entry . 9 . Any radiocontrastfacilitated study within 30 day prior Study Day 1 . 10 . Cerebrovascular accident within previous 6 month , transient ischemic attack within previous year . 11 . Pregnant nursing woman ; woman childbearing potential must negative serum pregnancy test Screen . 12 . Known adverse reaction losartan and/or ALA. 13 . Participation another clinical trial receive investigational agent reason within 30 day Study Day 1 . 14 . Any condition opinion Investigator , may adversely affect safety subject , subject 's ability complete study , outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes mellitis</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>Albuminuria</keyword>
</DOC>